Pfizer halts development of hep C drug filibuvir

03/13/2013 | Pharmaceutical Business Review Online

Pfizer said it would stop developing its midstage hepatitis C drug filibuvir, or PF-00868554. Potential competitors included new hepatitis C therapies from Gilead Sciences and AbbVie. "We continue to prioritize our [research and development] capital allocation to drive the next wave of innovative medicines and vaccines that bring benefit to patients and value to health care systems around the world," Pfizer's Victoria Davis said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD